{"image_url":null,"version":"1.0","author_url":"https://blog.hatena.ne.jp/okumi/","width":"100%","blog_title":"\u30ea\u30d7\u30ed\u306a\u65e5\u8a18","title":"\u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2\uff1a\u7d4c\u53e3\u4e2d\u7d76\u85acMS-2 Step\u306e\u51e6\u65b9\u5236\u9650\u304c\u7de9\u548c\u3055\u308c\u307e\u3057\u305f\uff082023\u5e747\u670811\u65e5\uff09","author_name":"okumi","type":"rich","blog_url":"https://okumi.hatenablog.com/","provider_name":"Hatena Blog","url":"https://okumi.hatenablog.com/entry/2023/08/17/221851","description":"Amendments to restrictions for prescribing of MS-2 Step (Mifepristone and Misoprostol), Published 11 July 2023 Amendments to restrictions for prescribing of MS-2 Step (Mifepristone and Misoprostol) | Therapeutic Goods Administration (TGA) \u4eee\u8a33\u3057\u307e\u3059\u3002 \u533b\u85ac\u54c1\u884c\u653f\u5c40\uff08The Therapeutic Goods Administration\uff1aTGA\uff09\u306f\u3001MS-2\u2026","provider_url":"https://hatena.blog","published":"2023-08-17 22:18:51","categories":[],"html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fokumi.hatenablog.com%2Fentry%2F2023%2F08%2F17%2F221851\" title=\"\u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2\uff1a\u7d4c\u53e3\u4e2d\u7d76\u85acMS-2 Step\u306e\u51e6\u65b9\u5236\u9650\u304c\u7de9\u548c\u3055\u308c\u307e\u3057\u305f\uff082023\u5e747\u670811\u65e5\uff09 - \u30ea\u30d7\u30ed\u306a\u65e5\u8a18\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","height":"190"}